As<unk>  is not metabolized in the liver and has a low affinity to plasma proteins, it is expected to have a low potential for interactions. An analysis of patient data showed no interactions with a range of other drugs; the exception is valproic acid, which slightly slows down<unk>  elimination from the body. Combining the drug with other myelosuppressants may increase the risk of myelosuppression.
Temozolomide
Vincristine
Carmustine
Bendamustine
Lomustine
Ifosfamide
Trifluridine
Doxorubicin